Table 1.

Coexpression of BCL-2, BIM, MCL-1, and BCL-XL in primary breast cancer subtypes

Breast cancer subtype (no.)BCL-2 expressionNo. of samples (%)BCL-2 histoscore% BIM positive (histoscore)% MCL-1 positive (histoscore)% BCL-XL positive (histoscore)
Luminal (54)+45 (83.3)6.89100 (6.73)97.7 (5.98)100 (8.74)
9 (16.7)88.9 (4.78)88.9 (6.11)100 (6.89)
HER2 (22)+11 (50.0)5.09100 (5.09)100 (5.00)100 (8.60)
11 (50.0)90.0 (5.30)100 (6.55)100 (8.20)
Basal-like (54)+10 (18.5)3.7077.8 (4.78)88.9 (5.00)100 (6.00)
44 (81.5)58.1 (2.09)92.9 (4.38)89.5 (6.29)
Marker-null (29)+12 (41.4)5.0075.0 (2.92)83.3 (3.17)83.3 (4.17)
17 (58.6)58.8 (3.65)52.9 (2.82)86.7 (4.80)
All tumors (159)+78 (49.1)5.9693.5 (5.68)94.7 (5.28)96.2 (7.49)
81 (50.9)65.8 (3.14)84.8 (4.54)92.1 (6.17)
  • Of 197 tumor samples in the tissue microarrays, scoring of all four markers was feasible for 159 tumors. For BCL-2 expression: (+) positive, (−) negative. The numbers in parentheses for BIM, MCL-1, and BCL-XL are the mean histoscores. Scoring of samples is described in SI Materials and Methods.